West Chester, OH, United States of America

Glen E Mieling


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 20(Granted Patents)


Company Filing History:


Years Active: 1998

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Glen E Mieling: Innovator in Pharmaceutical Compounds

Introduction

Glen E Mieling is a notable inventor based in West Chester, OH (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that interact with alpha-2 adrenoceptors. His work has implications for treating various disorders, showcasing the importance of innovation in medical science.

Latest Patents

Mieling holds a patent for a compound titled "6-(2-imidazolinylamino) quinolines useful as alpha-2 adrenoceptor." This invention relates to specific compounds that can be utilized in pharmaceutical compositions aimed at preventing or treating disorders modulated by alpha-2 adrenoceptors. The patent highlights the structure of these compounds and their potential therapeutic applications.

Career Highlights

Glen E Mieling is associated with The Procter & Gamble Company, where he has been able to apply his expertise in pharmaceutical innovation. His work at this esteemed company has allowed him to contribute to advancements in health and wellness products, emphasizing the role of research and development in improving lives.

Collaborations

Mieling has collaborated with notable colleagues such as Thomas L Cupps and Peter J Maurer. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to the development of impactful pharmaceutical solutions.

Conclusion

Glen E Mieling's contributions to the field of pharmaceuticals through his innovative patents and collaborations underscore the vital role of inventors in advancing medical science. His work continues to influence the development of treatments that can improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…